alendronate has been researched along with Atrial Fibrillation in 14 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To explore the incidence of atrial fibrillation (AF) and other cardiovascular endpoints in clinical trials of alendronate." | 8.88 | Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. ( Barrett-Connor, E; Bone, HG; de Papp, A; Hustad, CM; Liberman, UA; Papapoulos, S; Santora, AC; Swern, AS; Wang, H, 2012) |
| "To explore the incidence of atrial fibrillation (AF) and other cardiovascular endpoints in clinical trials of alendronate." | 4.88 | Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials. ( Barrett-Connor, E; Bone, HG; de Papp, A; Hustad, CM; Liberman, UA; Papapoulos, S; Santora, AC; Swern, AS; Wang, H, 2012) |
| "Alendronate sodium is used to reduce the risk of bone fracture in aged osteoporosis patients." | 3.96 | Transient increase in international normalized ratio (INR) and bleeding risk following Alendronate sodium in elderly patients on warfarin: Two case reports. ( Bian, P; Qian, S; Shi, L; Zhou, J, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (78.57) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Qian, S | 1 |
| Zhou, J | 1 |
| Bian, P | 1 |
| Shi, L | 1 |
| Strandberg, TE | 1 |
| Abrahamsen, B | 1 |
| Eiken, P | 1 |
| Brixen, K | 1 |
| Grosso, A | 1 |
| Douglas, I | 1 |
| Hingorani, A | 1 |
| MacAllister, R | 1 |
| Smeeth, L | 1 |
| Ringe, JD | 1 |
| Vestergaard, P | 1 |
| Schwartz, K | 1 |
| Pinholt, EM | 1 |
| Rejnmark, L | 1 |
| Mosekilde, L | 1 |
| Barrett-Connor, E | 1 |
| Swern, AS | 1 |
| Hustad, CM | 1 |
| Bone, HG | 1 |
| Liberman, UA | 1 |
| Papapoulos, S | 1 |
| Wang, H | 1 |
| de Papp, A | 1 |
| Santora, AC | 1 |
| Cummings, SR | 2 |
| Schwartz, AV | 1 |
| Black, DM | 1 |
| Karam, R | 1 |
| Camm, J | 1 |
| McClung, M | 1 |
| Zuber, MA | 1 |
| Lee, T | 1 |
| Cauley, JA | 1 |
| Ensrud, KE | 1 |
| Heckbert, SR | 1 |
| Li, G | 1 |
| Smith, NL | 1 |
| Psaty, BM | 1 |
1 review available for alendronate and Atrial Fibrillation
| Article | Year |
|---|---|
Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials.
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Cardiovascular Diseases; Dose-Re | 2012 |
13 other studies available for alendronate and Atrial Fibrillation
| Article | Year |
|---|---|
Transient increase in international normalized ratio (INR) and bleeding risk following Alendronate sodium in elderly patients on warfarin: Two case reports.
Topics: Aged; Aged, 80 and over; Alendronate; Anticoagulants; Atrial Fibrillation; Bone Density Conservation | 2020 |
Alendronate, osteoporosis, and atherosclerosis.
Topics: Alendronate; Atherosclerosis; Atrial Fibrillation; Bone Density Conservation Agents; Humans; Osteopo | 2008 |
Atrial fibrillation in fracture patients treated with oral bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Case-Co | 2009 |
Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation | 2009 |
[Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Clinical Trials as Topic; Diphos | 2009 |
Bisphosphonates and atrial fibrillation.
Topics: Aged; Alendronate; Atrial Fibrillation; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Ost | 2008 |
Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
Topics: Aged; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation Agents; Cohort Stu | 2010 |
Alendronate and atrial fibrillation.
Topics: Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Female; Fr | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diph | 2007 |
[Osteoporosis and bisphosphonates].
Topics: Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Dose-Respo | 2007 |
Ask the doctor. I am 86 years old and have been taking Fosamax to strengthen my bones for nearly 10 years. A few months ago, I suddenly fainted and was later diagnosed with atrial fibrillation. Did that happen because I was taking Fosamax?
Topics: Aged, 80 and over; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Humans; Osteo | 2007 |
Considering competing risks . . . Not all black and white.
Topics: Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Decision Making; Diabetes Mellit | 2008 |
Use of alendronate and risk of incident atrial fibrillation in women.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Case-Co | 2008 |